Catalyst Biosciences, Inc. (CBIO): Price and Financial Metrics

Catalyst Biosciences, Inc. (CBIO): $7.67

0.21 (-2.65%)

POWR Rating

Component Grades








Add CBIO to Watchlist
Sign Up

Industry: Biotech




#199 of 355

in industry

CBIO Price/Volume Stats

Current price $7.67 52-week high $8.69
Prev. close $0.53 52-week low $0.19
Day low $7.20 Volume 32,246
Day high $8.69 Avg. volume 763,526
50-day MA $0.50 Dividend yield N/A
200-day MA $0.33 Market Cap 291.27M

CBIO Stock Price Chart Interactive Chart >

Catalyst Biosciences, Inc. (CBIO) Company Bio

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on engineering proteases as therapeutics for hemophilia, hemeostasis, complement-mediated diseases, and other unmet medical needs. The company is based in South San Francisco, California.

CBIO Latest News Stream

Event/Time News Detail
Loading, please wait...

CBIO Latest Social Stream

Loading social stream, please wait...

View Full CBIO Social Stream

Latest CBIO News From Around the Web

Below are the latest news stories about CATALYST BIOSCIENCES INC that investors may wish to consider to help them evaluate CBIO as an investment opportunity.

Is Catalyst Biosciences (CBIO) Significantly Overvalued?

An Analysis of the Intrinsic Value and Future Prospects

Yahoo | August 23, 2023

Catalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 months

In the last year, multiple insiders have substantially increased their holdings of Catalyst Biosciences, Inc...

Yahoo | April 3, 2023

12 Cheap Healthcare Stocks to Buy in 2023

In this piece, we will take a look at the twelve cheap healthcare stocks to buy in 2023. For more healthcare stocks, head on over to 5 Cheap Healthcare Stocks to Buy in 2023. The healthcare sector is one of the few industries that has rapidly transformed itself in just a couple of decades. Modern […]

Yahoo | March 29, 2023

Catalyst Biosciences Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the Company’s previously announced asset purchase agreement with GNI Group Ltd (“GNI Group”) and GNI Hong Kong Limited (together “GNI”) to purchase all of the assets and intellectual property rights primarily related to GNI’s proprietary hydronidone compound outside of China (collectively, the “F351 Assets”)

Yahoo | February 28, 2023

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21

Yahoo | December 27, 2022

Read More 'CBIO' Stories Here

CBIO Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 126.76%
3-year -87.71%
5-year -93.53%
2023 0.00%
2022 -42.29%
2021 -85.52%
2020 -7.34%
2019 -13.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!